Experimental Eye Research, Год журнала: 2024, Номер 249, С. 110130 - 110130
Опубликована: Окт. 18, 2024
Язык: Английский
Experimental Eye Research, Год журнала: 2024, Номер 249, С. 110130 - 110130
Опубликована: Окт. 18, 2024
Язык: Английский
Biomedicine & Pharmacotherapy, Год журнала: 2025, Номер 183, С. 117857 - 117857
Опубликована: Янв. 17, 2025
Язык: Английский
Процитировано
1Cells, Год журнала: 2024, Номер 13(13), С. 1105 - 1105
Опубликована: Июнь 26, 2024
The cornea is continuously exposed to injuries, ranging from minor scratches deep traumas. An effective healing mechanism crucial for the restore its structure and function following major insults. Transforming Growth Factor-Beta (TGF-β), a versatile signaling molecule that coordinates various cell responses, has central role in corneal wound healing. Upon injury, TGF-β rapidly released into extracellular environment, triggering migration proliferation, differentiation of keratocytes myofibroblasts, initiation repair process. TGF-β-mediated processes are essential closure; however, excessive levels can lead fibrosis scarring, causing impaired vision. Three primary isoforms exist—TGF-β1, TGF-β2, TGF-β3. Although share many structural functional similarities, they present distinct roles regeneration, which adds an additional layer complexity understand Further, aberrant activity been linked pathologies, such as scarring Peter’s Anomaly. Thus, understanding molecular cellular mechanisms by TGF-β1-3 regulate will enable development potential therapeutic interventions targeting key this Herein, we summarize multifaceted healing, dissecting action interactions with other molecules, outline pathogenesis.
Язык: Английский
Процитировано
4Journal of Molecular Liquids, Год журнала: 2024, Номер unknown, С. 126541 - 126541
Опубликована: Ноя. 1, 2024
Язык: Английский
Процитировано
4Acta Histochemica, Год журнала: 2025, Номер 127(1), С. 152231 - 152231
Опубликована: Янв. 27, 2025
Язык: Английский
Процитировано
0Indus journal of bioscience research., Год журнала: 2025, Номер 3(1), С. 500 - 508
Опубликована: Янв. 29, 2025
Gene therapy has emerged as a novel strategy in the treatment of eye problems, bringing fresh hope for illnesses previously believed to be untreatable. Recent developments molecular biology and genetic engineering have enabled creation tailored medicines that address fundamental causes ocular rather than just treating symptoms. interventions are showing promise conditions including diabetic retinopathy, age-related macular degeneration, hereditary retinal dystrophies. The area undergone revolution because methods like CRISPR-Cas9 gene editing adeno-associated viral (AAV) vectors, which enable precise delivery change material within protected limited environment eye. Patients receiving these treatments shown notable increases visual acuity structural repair clinical studies. Furthermore, order overcome obstacles immunogenicity payload capacity, next-generation systems nanoparticles non-viral vectors emerging, could increase potential therapy. Although field is still developing quickly, ethical concerns, high expenses, requirement long-term safety assessments major problems. This review highlights latest disorders, discussing key breakthroughs, ongoing trials, future directions achieve widespread accessibility efficacy diseases.
Язык: Английский
Процитировано
0Journal of Materials Chemistry B, Год журнала: 2025, Номер unknown
Опубликована: Янв. 1, 2025
Corneal stromal defects cause global blindness and entail unmet solutions beyond transplants. This review highlights scaffolds, biomaterials, signaling cues in corneal stroma engineering to advance next-generation vision therapies.
Язык: Английский
Процитировано
0Advanced Drug Delivery Reviews, Год журнала: 2024, Номер 209, С. 115328 - 115328
Опубликована: Май 3, 2024
Язык: Английский
Процитировано
0Experimental Eye Research, Год журнала: 2024, Номер 249, С. 110130 - 110130
Опубликована: Окт. 18, 2024
Язык: Английский
Процитировано
0